The Tokyo All Star That Pays Dividends in Omaha
Warren Buffett helped restore the prestige of Japan’s conglomerates. In Brazil, the idea still tends to…
B3 · Bovespa
HYPE3 Hypera
Profile
Financials
Related news on Hypera
Hypera Enters Brazil’s GLP-1 Market as Anvisa Approves Five New Semaglutide Pens
Semavy, marketed under the Mantecorp brand, is expected to reach pharmacies within two months as Brazil…
Listed Healthcare Companies Create Nearly 80,000 Jobs, Expanding Headcount by 48% Since 2019
A BTG Pactual survey shows ten listed healthcare companies increased their combined workforce from about 166,000…
Hypera Pharma posts strong Q1 profit, revenue surge
Brazil’s Hypera Pharma (HYPE3.SA) reports 86.7% revenue jump and higher margins in Q1 2026, supported by…
Brazil’s 4Q25 earnings season looks weaker than it actually is
Excluding Petrobras, Vale and Braskem, earnings show stabilization — not deterioration — as revenue holds and…
Hypera confident in launching semaglutide in 2026
After patent expiry in March 2026, Hypera (HYPE3) aims to be among the first to sell…
Hypera Pharma posts R$453.9 million profit and record cash flow after working-capital overhaul
Net revenue rises 16%, EBITDA margin back to pre-optimization levels; company redeems costlier debt and reinforces…
Sanofi Advances Medley Sale, Plans Exit From Brazil Generics Market
Pharma executives in Brazil this week; Lazard advising, O Globo reports.
Brazilian drugmakers ready for Ozempic generic push
Anvisa to fast-track semaglutide generics; EMS, Hypera and Biomm eye 2026 rollout.
Market data by TradingView. Informational only — not investment advice.